Researchers conducted a cohort study to assess the effect of incretin receptor agonist therapy on continuous positive airway pressure use in T2D, obesity, and OSA.

About half (53%) of Americans say they hear or read about Ozempic, Wegovy and similar drugs extremely or very often.

GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

GoodRx reports transitioning from injectable to oral GLP-1s can simplify weight loss routines, but requires careful timing and consistency.

Here’s what the science says.

Objective: To investigate the association between fasting glucagon levels and coronary artery disease (CAD) risk in patients with Type 2 Diabetes Mellitus (T2DM). Methods: This cross-sectional study ...

About The Study: In this cohort of patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use was associated with significantly lower risks of vertebral compression ...

The UC Davis Innovation Institute for Food and Health recently hosted scientists, physicians and industry experts to discuss how drugs based on GLP-1 are transforming treatment for obesity, diabetes ...

Background: Glucagon-like peptide 1 (GLP-1) receptor agonists have demonstrated cardiovascular benefits in diabetic patients. However, their role in patients with dilated cardiomyopathy (DCM) without ...